Antitrust Antitrust

Simcere Pharmaceutical fined $16 million for abusive conduct in batroxobin-ingredient market (English version)

By MLex Staff
  • 25 Mar 2021 01:19
  • 25 Mar 2021 01:19
Below is an English translation of the decision, provided by MLex. The original decision in Chinese can be found here.

Simcere Pharmaceutical fined by China’s SAMR for abuse of dominance

Investigative procedures

In accordance with China’s Antimonopoly Law, the State Administration for Market Regulation (SAMR) initiated an investigation of Simcere Pharmaceutical Group in September 2020

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

TAKE A FREE TRIAL

Latest News